| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
25,700 |
1,906 |
$2.19M |
| J1756 |
Injection, iron sucrose, 1 mg |
5,236 |
1,367 |
$5K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
9,788 |
854 |
$3K |
| 90661 |
|
13 |
13 |
$479.05 |
| A4657 |
Syringe, with or without needle, each |
827 |
516 |
$357.90 |
| 83970 |
|
449 |
432 |
$0.00 |
| 85048 |
|
465 |
445 |
$0.00 |
| 85041 |
|
490 |
469 |
$0.00 |
| 85045 |
|
231 |
222 |
$0.00 |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
483 |
299 |
$0.00 |
| 83540 |
|
141 |
136 |
$0.00 |
| 82728 |
|
134 |
130 |
$0.00 |
| 90674 |
|
26 |
26 |
$0.00 |
| 0250 |
|
2,415 |
203 |
$0.00 |
| 82746 |
|
71 |
61 |
$0.00 |
| 83550 |
|
109 |
106 |
$0.00 |
| J1270 |
Injection, doxercalciferol, 1 mcg |
690 |
70 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
110 |
81 |
$0.00 |